Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis of Alzheimer's disease and related dementias and outmigration of older Puerto Rican Medicare Fee-for-service beneficiaries, 2012-2019.

The journals of gerontology. Series B, Psychological sciences and social sciences·2026
Same author

Lignin-Enhanced Biofoam for Gravity-Resistant Detoxification in Urban Environments.

ACS nano·2026
Same author

Omipalisib reduces hyperphosphorylated tau protein by modulating mTOR-autophagy pathway.

PloS one·2026
Same author

Helical quaternary amine polypeptide programs membrane stress to drive immunogenic cell death and cytosolic gene delivery for cancer immunotherapy.

Biomaterials·2026
Same author

End-Stage Renal Disease Treatment Choices Model and Use of Home Dialysis and Kidney Transplant.

JAMA health forum·2026
Same author

Mechanistic Underpinnings of Emotional Face Processing in Suicide Risk: Exploring the Moderating Effects of Cortisol on Neural Parameters Using Magnetoencephalography.

Psychiatric research and clinical practice·2026

Related Experiment Video

Updated: Jun 19, 2026

Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo
06:29

Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo

Published on: May 5, 2023

Glutathione-Responsive Inhalable Nanotherapeutics for Targeted Macrophage Reprogramming in Chronic Obstructive

Yoogyeong Oh1,2, Taihyun Kim1, Kyungtae Park1,3

  • 1Department of Chemical & Biomolecular Engineering, College of Engineering, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea.

Biomacromolecules
|June 18, 2026
PubMed
Summary

This study introduces AIR, an inhaled nanotherapeutic that delivers nitric oxide (NO) to target inflammation in chronic obstructive pulmonary disease (COPD). AIR effectively reduces lung inflammation by reprogramming M1 macrophages, offering a promising new treatment for COPD patients.

More Related Videos

Harvesting Murine Alveolar Macrophages and Evaluating Cellular Activation Induced by Polyanhydride Nanoparticles
11:26

Harvesting Murine Alveolar Macrophages and Evaluating Cellular Activation Induced by Polyanhydride Nanoparticles

Published on: June 8, 2012

Related Experiment Videos

Last Updated: Jun 19, 2026

Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo
06:29

Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo

Published on: May 5, 2023

Harvesting Murine Alveolar Macrophages and Evaluating Cellular Activation Induced by Polyanhydride Nanoparticles
11:26

Harvesting Murine Alveolar Macrophages and Evaluating Cellular Activation Induced by Polyanhydride Nanoparticles

Published on: June 8, 2012

Area of Science:

  • Nanomedicine
  • Pulmonary Medicine
  • Immunology

Background:

  • Chronic inflammation is central to chronic obstructive pulmonary disease (COPD) progression and symptom severity.
  • Nitric oxide (NO) possesses anti-inflammatory and airway-relaxing properties beneficial for COPD treatment.
  • Challenges exist in achieving targeted and sustained NO delivery for effective COPD therapy.

Purpose of the Study:

  • To develop an inhaled nanotherapeutic, AIR (Anti-Inflammatory Relaxer), for targeted NO delivery to M1 macrophages in COPD.
  • To investigate AIR's ability to reduce airway inflammation and promote M1 macrophage polarization into anti-inflammatory phenotypes.
  • To assess AIR's biocompatibility and potential for reduced lung bioaccumulation.

Main Methods:

  • AIR nanoparticles were constructed using dendritic mesoporous silica nanoparticles (DMSNs) functionalized with hyaluronic acid (HA) and diazeniumdiolates (NONOates).
  • HA facilitated targeted delivery to CD44-overexpressing M1 macrophages.
  • Intracellular glutathione was utilized to trigger NO release via disulfide bond cleavage, ensuring biocompatibility.

Main Results:

  • AIR nanoparticles selectively targeted and were internalized by M1 macrophages.
  • Targeted NO delivery induced M1 macrophage polarization towards an anti-inflammatory phenotype.
  • The nanotherapeutic demonstrated excellent biocompatibility due to glutathione-mediated release.

Conclusions:

  • Inhaled AIR nanotherapeutics show significant potential for treating chronic airway inflammation in COPD.
  • AIR offers a targeted approach to deliver nitric oxide, reprogramming M1 macrophages to alleviate COPD-related inflammation.
  • This strategy may reduce pulmonary bioaccumulation, enhancing safety and efficacy for COPD management.